[1]陈 楠,王光辉△,贺 赛,等.养正合剂改善乳腺癌术后化疗者不适及对患者细胞因子、红细胞免疫的影响[J].陕西中医,2019,(10):1357-1360.
　CHEN Nan,WANG Guanghui,HE Sai,et al.Yangzheng mixture improves the discomfort of postoperative chemotherapy in patients with breast cancer and its immunity to cytokines and red blood cells[J].,2019,(10):1357-1360.
点击复制

养正合剂改善乳腺癌术后化疗者不适及对患者细胞因子、红细胞免疫的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年10期
页码:
1357-1360
栏目:
临床研究
出版日期:
2019-10-05

文章信息/Info

Title:
Yangzheng mixture improves the discomfort of postoperative chemotherapy in patients with breast cancer and its immunity to cytokines and red blood cells
文章编号:
DOI:10.3969/j.issn.10007369.2019.10.011
作者:
陈 楠1; 王光辉2△; 贺 赛1; 刘 华1; 丁艳妮1; 党诚学2; 袁 权1
1.陕西省肿瘤医院乳腺科（西安 710061）；2.西安交通大学第一附属医院普通外科（西安 710061）
Author(s):
CHEN Nan; WANG Guanghui; HE Sai; et al.
Department of Breast Surgery,Shaanxi Cancer Hospital（Xi’an 710061）
关键词:
乳腺癌; 术后化疗; 养正合剂; 细胞因子; 红细胞免疫状态
Keywords:
Key words 〖HT5”SS〗Yangzheng mixture; Breast cancer; Postoperative chemotherapy; Cytokines; Erythrocyte immune status
分类号:
R737.9
文献标志码:
A
摘要:
摘 要 目的：观察养正合剂改善乳腺癌术后化疗者机体不适感及对患者细胞因子、红细胞免疫状态的影响。方法：选取乳腺癌术后化疗者120例，采用随机数字表法分为对照组和观察组，每组各60例。对照组一般支持治疗联合康艾注射液、观察组一般支持治疗联合养正合剂。观察和比较两组患者化疗前后机体不适症状及血常规、细胞因子、红细胞免疫状态。结果：化疗后，观察组恶心呕吐、食欲下降评分高于化疗前，对照组疲乏、恶心呕吐、呼吸困难、失眠、食欲下降、腹泻评分高于化疗前；观察组不适症状评分低于对照组，差异有统计学意义（P＜0.05）。化疗后，观察组WBC计数低于化疗前，对照组WBC计数低于化疗前，TNFα、IL6水平高于化疗前；观察组WBC计数高于对照组，TNFα、IL6水平低于对照组，差异均有统计学意义（P＜0.05）。化疗后，观察组FEER水平低于化疗前、FEIR和RBCICR水平高于化疗前，但差异无统计学意义（P＞0.05）；对照组差异有统计学意义（P＜0.05）。且观察组FEER水平高于对照组，FEIR和RBCICR水平低于对照组，差异均有统计学意义（P＜0.05）。结论：养正合剂通过减少乳腺癌术后化疗者机体炎性细胞因子大量释放、改善红细胞免疫状态，利于减轻患者术后化疗者疲乏无力等机体不适感且效果显著、作用确切，不失为一种有效的联合干预方法。
Abstract:
Abstract 〖HT5”SS〗Objective：To observe the effect of Yangzheng mixture on the body discomfort and the immune status of cytokines and erythrocytes in patients with breast cancer after chemotherapy. Methods：120 patients with postoperative chemotherapy for breast cancer were selected and divided into control group and observation group by random number table method，60 cases in each group. The control group generally supported the treatment combined with Kang，ai injection，and the observation group generally supported the treatment of the combination of Yangzheng mixture. The symptoms and blood routine，cytokines and erythrocyte immune status of the two groups were observed and compared before and after chemotherapy. Results：After chemotherapy，the nausea and vomiting and appetite decline scores in the observation group were higher than those before chemotherapy. The control group was fatigued，nausea and vomiting，dyspnea，insomnia，loss of appetite，and diarrhea scores before chemotherapy. The discomfort score of the observation group was lower than that of the control group. The difference was statistically significant (P＜0.05). After chemotherapy，the WBC count in the observation group was lower than that before chemotherapy. The WBC count of the control group was lower than that before chemotherapy，and the levels of TNFα and IL6 were higher than those before chemotherapy. The WBC count of the observation group was higher than that of the control group，TNFα，IL6. The level was lower than the control group，and the difference was statistically significant (P＜0.05). After chemotherapy，the FEER level in the observation group was lower than that before chemotherapy，FEIR and RBCICR levels were higher than those before chemotherapy，but the difference was not statistically significant (P＞0.05). The difference in the control group was statistically significant (P＜0.05). The FEER level in the observation group was higher than that in the control group，and the FEIR and RBCICR levels 〖LM〗were lower than the control group，and the difference was statistically significant (P＜0.05). Conclusion：Yangzheng mixture can reduce the body's inflammatory cytokine release and improve the red blood cell immune status after chemotherapy，which is beneficial to alleviate the body discomfort such as fatigue and weakness of postoperative chemotherapy，and the effect is remarkable and effective. 

参考文献/References:

[1] 王 冰，王 欣，何代玉，等.君子扶正汤对结直肠癌患者术后化疗减毒增效及增强免疫力方面的临床研究[J].中华保健医学杂志，2016，18（3）：236237.
[2] Meissner M，Addeo A.Intrathecal methotrexate and craniospinal radiotherapy can be an effective treatment of carcinomatous meningitis in patients with breast cancer：case reports[J]. Case Rep Oncol，2016，9（3）：586592.
[3] Gerber L H.Cancerrelated fatigue：persistent，pervasive，and problematic[J].Phys Med Rehabil Clin N Am，2017，28（1）：6588.
[4] 李 琛，王笑民.癌因性疲乏治疗研究进展[J].中华中医药杂志，2015，30（4）：11771180.
[5] 黄德良，姚中平，张卫忠.PD1抑制剂派姆单抗对晚期非小细胞肺癌T淋巴细胞亚群及NK细胞的影响[J].国际肿瘤学杂志，2017，44（3）：169172.
[6] Levkovich I，Cohen M，Pollack S，et al.Cancerrelated fatigue and depression in breast cancer patients postchemotherapy：Different associations with optimism and stress appraisals[J]. Palliat Support Care，2015，13（5）：11411151.
[7] 李长生，金阿荣，高晓会，等.临床常见良恶性肿瘤的诊断与治疗[M].长春：吉林科学技术出版社，2014：5556.
[8] Mahoney KM，Rennert PD，Freeman GJ.Combination cancer immunotherapy and new immunomodulatory targets[J]. Nat Rev Drug Discov，2015，14（8）：561584.
[9] 丁金霞，王 婷，王维利，等.化疗期癌症患者癌因性疲乏与生命质量的研究[J].中华疾病控制杂志，2015，19（5）：462465.
[10] Plotti F，Scaletta G，Capriglione S，et al.The role of HE4，a novel biomarker，in predicting optimal cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer[J].Int J Gynecol Cancer，2017，27（4）：696702.
[11] Pogge von Strandmann E，Reinartz S，Wager U，et al.Tumorhost cell interactions in ovarian cancer：pathways to therapy failure[J].Trends Cancer，2017，3（2）：137148.
[12] 石瑞平，郭树霞，秦 娜，等.恶性血液病患者医院感染病原菌对血清炎性因子的影响研究[J].中华医院感染学杂志，2016，26（3）：599601.
[13] 党 东，雷 斌.艾灸、穴位注射、药物治疗对肿瘤气血亏虚证患者生活质量的影响[J].陕西中医，2015，35（9）：11971198.

相似文献/References:

[1]张贺,姜大庆.鸦胆子素D对乳腺癌MDAMB231细胞增殖与凋亡及细胞周期的影响*[J].陕西中医,2019,(11):1495.
　ZHANG He,JIANG Daqing..Effects of Bruceine D on proliferation,apoptosis and cell cycle of breast cancer MDAMB231 cells[J].,2019,(10):1495.
[2]张栓宝,张燕平△,严宁娟.康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子及生活质量的影响[J].陕西中医,2019,(11):1566.
　ZHANG Shuanbao,ZHANG Yanping,YAN Ningjuan..Effect of Kanglaite injection on immune function,VEGF and quality of life in patients with breast cancer receiving neoadjuvant chemotherapy[J].,2019,(10):1566.
[3]贺晓立,王 军,余 静,等.沈力教授治疗乳腺癌十一法*[J].陕西中医,2020,(1):92.
　HE Xiaoli,WANG Jun,YU Jing,et al.Professor SHEN Li’s treatment of breast cancer by using eleven TCM methods[J].,2020,(10):92.
[4]刘歆春,李锁南,黄飞燕.乳岩汤联合西药治疗乳腺癌疗效及对患者免疫功能的影响[J].陕西中医,2021,(9):1201.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.012]
[5]冯秀梅,马 兰,罗玉群,等.益气活血方对乳腺癌MCF-7细胞系增殖侵袭能力及miR-100表达水平影响的研究[J].陕西中医,2021,(11):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
　FENG Xiumei,MA Lan,LUO Yuqun,et al.Yiqi Huoxue recipe to inhibit breast cancer cell proliferation and invasion and increase the expression of miR-100[J].,2021,(10):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
[6]陈 军,孙 嫘,惠建荣,等.艾灸对三阴性乳腺癌移植瘤小鼠生存期的影响及机制研究[J].陕西中医,2022,(7):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
　CHEN Jun,SUN Lei,HUI Jianrong,et al.Effect and mechanism of moxibustion on survival of triple negative breast cancer transplanted tumor mice[J].,2022,(10):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
[7]陈明明,郭 旭,熊乙霓,等.培元固本法治疗乳腺癌化疗后骨髓抑制临床研究[J].陕西中医,2022,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.014]
[8]蔡丽珍,白瑞娜,张 路,等.基于“痰夹瘀血”理论探讨乳腺癌相关淋巴水肿因机治疗[J].陕西中医,2023,(10):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
　CAI Lizhen,BAI Ruina,ZHANG Lu,et al.Based on the theory of “phlegm blended with blood stasis”,to explore the mechanism and treatment of breast cancer related lymphedema[J].,2023,(10):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
[9]宋铁兵,李康乐,马 强,等.土贝母皂苷甲对乳腺癌细胞MCF-7凋亡的影响[J].陕西中医,2023,(11):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]
　SONG Tiebing,LI Kangle,MA Qiang,et al.Effect of Tubeimoside I on apoptosis of breast cancer cell MCF-7[J].,2023,(10):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]
[10]高 宏,周立江,邢向荣,等.柴胡龙骨牡蛎汤加减治疗乳腺癌研究进展[J].陕西中医,2023,(11):1657.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.040]
　GAO Hong,ZHOU Lijiang,XING Xiangrong,et al.Research progress of Chaihu Longgu Muli decoction in treatment of breast cancer[J].,2023,(10):1657.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.040]

更新日期/Last Update: 2019-10-23